Evidence map›Paper›PMID 30788382›Full record

ArticleMolecular therapy. Methods & clinical development2019

Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs.

Margherita Alba Carlotta Pomatto, Benedetta Bussolati, Sergio D'Antico, Sara Ghiotto, Ciro Tetta, Maria Felice Brizzi, Giovanni Camussi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 2 syntheses or guidelines pooled it, 225 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Margherita Alba Carlotta PomattoDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Benedetta BussolatiDepartment of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.
Sergio D'AnticoBlood Bank, A.O.U. Città della Salute e della Scienza, 10126 Turin, Italy.
Sara GhiottoBlood Bank, A.O.U. Città della Salute e della Scienza, 10126 Turin, Italy.
Ciro TettaUnicyte srl, 10126 Turin, Italy.
Maria Felice BrizziDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Giovanni CamussiDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) carry various molecules involved in intercellular communication and have raised great interest as drug delivery systems. Several engineering methods have been investigated for vesicle loading. Here, we studied the electroporation of EVs isolated from plasma to load antitumor microRNAs (miRNAs). First, we optimized the transfection protocol using miRNA cel-39 by evaluating different parameters (voltage and pulse) for their effect on vesicle morphology, loading capacity, and miRNA transfer to target cells. When compared with direct incubation of EVs with miRNA, mild electroporation allowed more efficient loading and better protection of miRNA from RNase degradation. Moreover, electroporation preserved the naive vesicle cargo, including RNAs and proteins, and their ability to be taken up by target cells, supporting the absence of vesicle damage. EVs engineered with antitumor miRNAs (miR-31 and miR-451a) successfully promoted apoptosis of the HepG2 hepatocellular carcinoma cell line, silencing target genes involved in anti-apoptotic pathways. Our findings indicate an efficient and functional miRNA encapsulation in plasma-derived EVs following an electroporation protocol that preserves EV integrity.

Indexed as

cancer therapydrug deliveryelectroporationexosomehepatocarcinomamiR-31miR-451amiRNA enrichmentmiRNA loadingvesicle engineering

Identifiers

PMID30788382
PMCPMC6370572
OpenAlexW2910555711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.